CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis.
Cutaneous leishmaniasis (CL) affects the lives of 0.7-1 million people every year causing lesions that take months to heal. These lesions can result in disfiguring scars with psychological, social and economic consequences. Antimonials are the first line of therapy for CL, however the treatment is l...
Saved in:
Main Authors: | Seth G Thacker (Author), Ian L McWilliams (Author), Beatrice Bonnet (Author), Lydia Halie (Author), Serge Beaucage (Author), Swaksha Rachuri (Author), Ranadhir Dey (Author), Robert Duncan (Author), Farrokh Modabber (Author), Stephen Robinson (Author), Graeme Bilbe (Author), Byron Arana (Author), Daniela Verthelyi (Author) |
---|---|
Format: | Book |
Published: |
Public Library of Science (PLoS),
2020-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Characteristic of K3 (CpG-ODN) as a Transcutaneous Vaccine Formulation Adjuvant
by: Sayami Ito, et al.
Published: (2020) -
Plasmacytoid Dendritic Cell Response to CpG ODN Correlates with CXCL16 Expression and Is Inhibited by ox-LDL
by: Mayda Gursel, et al.
Published: (2013) -
Evaluation of CpG-ODN-Adjuvanted <i>Toxoplasma gondii</i> Virus-Like Particle Vaccine upon One, Two, and Three Immunizations
by: Hae-Ji Kang, et al.
Published: (2020) -
Ionizable Lipid Nanoparticles Enhanced the Synergistic Adjuvant Effect of CpG ODNs and QS21 in a Varicella Zoster Virus Glycoprotein E Subunit Vaccine
by: Ning Luan, et al.
Published: (2022) -
CpG immunostimulatory oligodeoxynucleotide 1826 as a novel nasal ODN adjuvant enhanced the protective efficacy of the periodontitis gene vaccine in a periodontitis model in SD rats
by: Guohui Bai, et al.
Published: (2021)